Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:CTSO

Cytosorbents Q3 2024 Earnings Report

Cytosorbents logo
$0.35 -0.03 (-8.81%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.35 0.00 (-0.57%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cytosorbents EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cytosorbents Revenue Results

Actual Revenue
$8.61 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cytosorbents Announcement Details

Quarter
Q3 2024
Date
1/3/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cytosorbents' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Cytosorbents Earnings Headlines

Cytosorbents (NASDAQ:CTSO) Shares Scheduled to Reverse Split on Tuesday, September 8th
September 4 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001746
CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor
September 3 at 2:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ctso-cytosorbents-announces-very-positive-093100484.html
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.tc pixel
September 4 at 1:00 AM  |  Paradigm Press (Ad)
Cytosorbents To Implement 1-For-20 Reverse Stock Split, Stock Down In Pre-Market
September 3 at 9:27 AM  |  rttnews.comhttps://www.rttnews.com/3688243/cytosorbents-to-implement-1-for-20-reverse-stock-split-stock-down-in-pre-market.aspx
CytoSorbents Announces Reverse Stock Split
September 3 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-announces-reverse-stock-split-302868315.html
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
September 2 at 7:28 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-bleeding-using-cytosorb-in-cabg-patients-on-ticagrelor-and-updates-recent-drugsorb-atr-fda-pre-submission-meetings-302867656.html
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO), founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.

View Cytosorbents Profile
Earnings Tools